ScreenPoint Medical's Transpara AI Chosen for $16M Breast Cancer Screening Trial

September 24, 2025
ScreenPoint Medical's Transpara AI has been selected for the PRISM Trial, a $16 million study in the U.S. to evaluate AI's role in breast cancer screening.

ScreenPoint Medical has announced that its Transpara breast imaging AI solution will be used in the PRISM Trial, a significant randomized controlled trial in the United States. Announced in a press release, the trial is funded by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI) and aims to assess the effectiveness of AI in breast cancer screening.

The PRISM Trial, led by UCLA and UC Davis, will explore whether AI can assist radiologists in detecting breast cancer earlier, improving mammography accuracy, and reducing unnecessary patient callbacks. The study will involve hundreds of thousands of mammograms interpreted at leading academic medical centers, including UCLA, UC Davis, and others.

ScreenPoint Medical's Transpara Detection software will be integrated into the clinical workflow using the Aidoc aiOS platform, supporting the trial's objectives to enhance early breast cancer detection and improve patient-centered care systems.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/25
Burnt Secures $3.8M to Automate Food Supply Chains with AI
09/25
Thyme Care Secures $97M Series D to Expand AI-Driven Oncology Solutions
09/25
NAVER D2SF Invests in GravityLabs for Health Habit Platform Expansion
09/25
Beroe Secures $34 Million to Enhance Procurement Intelligence
09/24
Cohere Secures Additional $100 Million, Valuation Hits $7 Billion

More from: Life Sciences

09/25
RamSoft Integrates Koios AI for Enhanced Cancer Diagnosis
09/25
Infinitus Systems Introduces MCP Server for Healthcare AI Interoperability
09/25
Avant Technologies Enters Longevity Biotech with Klothonova Joint Venture
09/25
Thyme Care Secures $97M Series D to Expand AI-Driven Oncology Solutions
09/25
Digital Pathology Market to Reach $3.86 Billion by 2033

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like